Propeller Health, a digital health company developing solutions respiratory medicine has released the first ever API to provide local asthma conditions to anyone across the United States. The new service, Air by Propeller, is open and free to use that enables other individuals and organizations to use its local asthma condition calculations to improve the health of people with chronic respiratory disease.Propeller has trained a machine learning model based on millions of days of anonymized data
Read More
respiratory Apps
ResApp Licenses New Algorithm to Improve Diagnostic Screening for Childhood Pneumonia
ResApp Health Limited, a digital health startup provider of smartphone apps for respiratory disease diagnosis and management has signed a licensing agreement with UniQuest, the main commercialization company of The University of Queensland. The licensing agreement includes an additional diagnostic toolset of machine-learning algorithms that use a combination of clinical features to screen for childhood pneumonia. Pneumonia is the leading cause of mortality for children below five years of age.
Read More
Cohero Health Adds Strategic Investors Samsung NEXT, Omron Health to Support Commercialization of BreatheSmart
Cohero Health, a NYC-based digital health company developing connected health tools and technologies to empower respiratory patients and improve care through smart mobile devices, has added strategic investors Samsung NEXT and Omron Healthcare to its oversubscribed Series A round. The company originally announced its $9M Series A in late 2016 but elected to allow forthe investment of additional strategic capital. With the addition of the two new strategic investors/partners, the Series A round
Read More
ResApp Expands Research Collaboration With Mass General for Diagnostic App
ResApp, a Australian-based digital health startup that has developed a smartphone app that can diagnose respiratory diseases based on the sound signatures of the coughs has entered into a two-year expanded research collaboration with Massachusetts General Hospital (MGH). As part of the research collaboration, ResApp and MGH will perform additional analysis of the SMARTCOUGH-C study data, use the SMARTCOUGH-C dataset to investigate the state of respiratory disease clinical practice today and
Read More
Propeller Health Lands FDA 510(k) Clearance to Market Sensor for the Ellipta Inhaler
Propeller Health, a Madison, Wisconsin-based provider of digital solutions for respiratory medicine has received FDA 510(k) clearance to market its digital sensor for use with GSK’s Ellipta® patented, dry powder inhaler. The custom sensor designed exclusively for the Ellipta inhaler was cleared as part of a R&D collaboration between Propeller and GSK announced in late 2015.For the R&D collaboration, the Propeller sensor automatically collected and recorded data on the Ellipta inhaler's
Read More
Propeller Health Lands $21.5M to Modernize Respiratory Disease Management
Propeller Health, a digital solution for respiratory medicine has raised $21.5 million in Series C funding from 3M Ventures, S.R. One, Limited, Hikma Ventures and existing investors Safeguard Scientifics and Social Capital. The round also includes participation from existing investors Safeguard Scientifics and Social Capital. The company plans to utilize the funding to expand Propeller’s FDA-cleared digitally-guided therapy platform. Despite an abundance of effective medications, the burden of
Read More
Propeller, Health Vectura Partner To Develop Connected Dry-Powder Inhaler
Digital health company Propeller Health is teaming up with respiratory pharmaceutical company Vectura to develop digitally connected dry powder inhaler (“DPI”) technology inhalers integrated with Propeller's FDA-cleared digital health platform. The partnership will bring a new connected dry-powder inhaler device onto the Propeller platform. Vectura provides a range of pre-metered foil blister-based dry powder inhalers developed to meet patients’ needs in inhalation therapy. The initial focus of
Read More
ResApp Nabs $12.5M For Smartphone App That Instantly Diagnose Respiratory Diseases
ResApp, a Australian-based digital health startup that has developed a smartphone app that can diagnose respiratory diseases based on the sound signatures of the coughs, announced it has raised $12.5 million in funding. The oversubscribed round was led by Jett Capital Advisors, Empire Capital Partners and CPS Capital Group. The company plans to use the funding to accelerate the FDA approval for its adult diagnostic test and expand US market access beyond telehealth into in-clinic use, including
Read More
